USA 104 , 25012506 (2007)
View at Publisher | View at Google Scholar Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, et al
Because youve got over half the people dropping off the drug because of side effects within a year
As female-physiology body composition research has matured, two compounds have emerged as the dominant reference points for investigating visceral fat specifically: Tesamorelin, a stabilized Growth Hormone Releasing Hormone (GHRH) analog with a uniquely well-documented visceral-fat research profile, and Retatrutide, an engineered triple agonist peptide studied for aggressive, multi-pathway metabolic effects
Weight loss is a significant consideration for both medications, especially given the obesity epidemic and its association with conditions like Type 2 Diabetes